Metabolomic profiles altered by erlotinib encapsulated in poly(lactide-co-glycolide) nanoparticles in non-small cell lung cancer
The encapsulation of erlotinib with PLGA showed effects and influenced critical metabolic pathways, especially pointing out the need to lower drug resistance and signifying it's potential use as an effective treatment strategy for NSCLC.
Authors
- Özgür Eşi̇m (ORCID: https://orcid.org/0000-0002-6402-156X)
- Ayhan Savaşer (ORCID: https://orcid.org/0000-0001-8342-2919)
- Emirhan Nemutlu (ORCID: https://orcid.org/0000-0002-7337-6215)
- Çiğdem Yücel (ORCID: https://orcid.org/0000-0003-2647-440X)
- Yalçın Özkan (ORCID: https://orcid.org/0000-0001-5163-6867)
- Taner Özgürtaş (ORCID: https://orcid.org/0000-0003-1110-6671)
- Engin Koçak (ORCID: https://orcid.org/0000-0002-1076-1300)
- Sevilay Erdoğan Kablan (ORCID: https://orcid.org/0000-0002-6503-0142)
- Ahmet Rıfat Balik (ORCID: https://orcid.org/0000-0002-3893-9721)
- Nurgül K. Bakırhan (ORCID: https://orcid.org/0000-0001-5469-9142)
- Meryem Ertugrul
- Síbel A. Özkan (ORCID: https://orcid.org/0000-0001-7494-3077)
- Cansel Köse Özkan (ORCID: https://orcid.org/0000-0002-4340-7279)
Institutions
- Ankara University (TR)
- University of Health Sciences (SO)
- Hacettepe University (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- Drug Development and Industrial Pharmacy
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1080/03639045.2025.2484326
- Citations
- 1
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94